437 related articles for article (PubMed ID: 30734187)
1. Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles.
Weers JG; Miller DP; Tarara TE
AAPS PharmSciTech; 2019 Feb; 20(3):103. PubMed ID: 30734187
[TBL] [Abstract][Full Text] [Related]
2. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
3. Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs.
Ke WR; Chang RYK; Kwok PCL; Chen D; Chan HK
Int J Pharm; 2020 Dec; 591():119984. PubMed ID: 33069893
[TBL] [Abstract][Full Text] [Related]
4. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
5. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
[TBL] [Abstract][Full Text] [Related]
6. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
Saboti D; Maver U; Chan HK; Planinšek O
J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
[TBL] [Abstract][Full Text] [Related]
7. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
Thi TH; Danède F; Descamps M; Flament MP
Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
[TBL] [Abstract][Full Text] [Related]
8. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation.
Lee HJ; Lee HG; Kwon YB; Kim JY; Rhee YS; Chon J; Park ES; Kim DW; Park CW
Eur J Pharm Sci; 2018 May; 117():279-289. PubMed ID: 29510172
[TBL] [Abstract][Full Text] [Related]
9. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery.
Duan J; Vogt FG; Li X; Hayes D; Mansour HM
Int J Nanomedicine; 2013; 8():3489-505. PubMed ID: 24092972
[TBL] [Abstract][Full Text] [Related]
10. The PulmoSphere™ platform for pulmonary drug delivery.
Weers J; Tarara T
Ther Deliv; 2014 Mar; 5(3):277-95. PubMed ID: 24592954
[TBL] [Abstract][Full Text] [Related]
11. Co-spray dried hydrophobic drug formulations with crystalline lactose for inhalation aerosol delivery.
Ke WR; Kwok PCL; Khanal D; Chang RYK; Chan HK
Int J Pharm; 2021 Jun; 602():120608. PubMed ID: 33862136
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Dry Powder Inhaler Carrier Targeted Design: A Comparative Case Study of Diverse Anomeric Compositions and Physical Properties of Lactose.
Pinto JT; Zellnitz S; Guidi T; Roblegg E; Paudel A
Mol Pharm; 2018 Jul; 15(7):2827-2839. PubMed ID: 29856921
[TBL] [Abstract][Full Text] [Related]
13. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
14. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
15. Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.
Mangal S; Nie H; Xu R; Guo R; Cavallaro A; Zemlyanov D; Zhou QT
Pharm Res; 2018 Jan; 35(2):28. PubMed ID: 29374368
[TBL] [Abstract][Full Text] [Related]
16. Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.
Mangal S; Xu R; Park H; Zemlyanov D; Shetty N; Lin YW; Morton D; Chan HK; Li J; Zhou QT
Pharm Res; 2018 Nov; 36(1):6. PubMed ID: 30406281
[TBL] [Abstract][Full Text] [Related]
17. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats.
Carvalho SR; Watts AB; Peters JI; Liu S; Hengsawas S; Escotet-Espinoza MS; Williams RO
Eur J Pharm Biopharm; 2014 Sep; 88(1):136-47. PubMed ID: 24859653
[TBL] [Abstract][Full Text] [Related]
18. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations.
Louey MD; Van Oort M; Hickey AJ
Pharm Res; 2004 Jul; 21(7):1207-13. PubMed ID: 15290861
[TBL] [Abstract][Full Text] [Related]
19. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
[TBL] [Abstract][Full Text] [Related]
20. Particle engineering of materials for oral inhalation by dry powder inhalers. II-Sodium cromoglicate.
Nolan LM; Li J; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2011 Feb; 405(1-2):36-46. PubMed ID: 21129460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
